About Us

We're here to transform the lives of people affected by neuromuscular disease.

Press Releases

Former MDA President and Chairman Bob Bennett, Broadcast and MDA Love Network Pioneer

Submitted by KReddy on Wed, 11/30/2016 - 13:47

CHICAGO, Dec.1, 2016 - In response to the passing of legendary broadcast executive Robert M. Bennett, former president, chairman and emeritus member of the Muscular Dystrophy Association Board of Directors, the extended MDA family today mourns his loss. Bob was 89 and lived in Newport Beach, California, with his wife of 66 years Marjie.
Jiffy Lube® and MDA Celebrate Five Years of Partnership on #GivingTuesday

Submitted by KReddy on Tue, 11/29/2016 - 11:51

Break $5 Million Mark in Funds Raised to Support Kids and Adults with Muscular Dystrophy
Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy

Submitted by KReddy on Mon, 11/07/2016 - 11:06

- Second Positive Phase 3 Study Provides Further Evidence of SPINRAZA’s Efficacy and Favorable Safety Profile -

- Results Were Statistically Significant and Clinically Meaningful -

Monday, November 7, 2016 7:30 am EST
Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA

Submitted by aquintero on Fri, 10/28/2016 - 15:51

CAMBRIDGE, Mass. – (BUSINESS WIRE) – Biogen (NASDAQ: BIIB) today announced that its New Drug Application (NDA) for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), has been accepted by the U.S.
MDA and RYR-1 Foundation Partner to Advance Research and Care for RYR1-Related Myopathies

Submitted by KReddy on Wed, 10/19/2016 - 22:10

CHICAGO, October 20, 2016 – The Muscular Dystrophy Association (MDA) and RYR-1 Foundation today announced a partnership aimed at advancing research and clinical care, raising awareness, and improving education of patients, medical professionals and the public about RYR1-related myopathies.

The partnership represents a key step in MDA’s commitment to form collaborative relationships with other organizations working on the same diseases MDA covers.
MDA and Target ALS Foundation Partner to Advance ALS Research and Therapy Development

Submitted by KReddy on Wed, 09/28/2016 - 08:47

Alliance Focuses On Supporting Promising, Young ALS Investigators

CHICAGO, September 28, 2016 – The Muscular Dystrophy Association (MDA) and Target ALS Foundation today announced a partnership aimed at advancing ALS research and therapy development. Through the alliance, the two organizations will work together to support talented, young scientists who choose to pursue a career devoted to ALS research.

« first
‹ previous
…
6
7
8
9
10
11
12
13
14
…
next ›
last »

Our Story

Our Team

Resources

Care Centers

Resource Center

Summer Camp

Our Approach

For Researchers

For Clinicians

Participate

Donate

Partner

About Us

Press Releases

Former MDA President and Chairman Bob Bennett, Broadcast and MDA Love Network Pioneer

Jiffy Lube® and MDA Celebrate Five Years of Partnership on #GivingTuesday

Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy

Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA

MDA and RYR-1 Foundation Partner to Advance Research and Care for RYR1-Related Myopathies

MDA and Target ALS Foundation Partner to Advance ALS Research and Therapy Development

Find MDA
in your Community

Sign Up for MDA News & Updates

About Us

Press Releases

Former MDA President and Chairman Bob Bennett, Broadcast and MDA Love Network Pioneer

Jiffy Lube® and MDA Celebrate Five Years of Partnership on #GivingTuesday

Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy

Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA

MDA and RYR-1 Foundation Partner to Advance Research and Care for RYR1-Related Myopathies

MDA and Target ALS Foundation Partner to Advance ALS Research and Therapy Development

Find MDA in your Community

Find MDA
in your Community